COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,946 Articles (22,604 medRxiv, 8,342 bioRxiv)

Most recent first Previous |  Page 3092: Articles 30911-30920  | Next

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
Hoffmann, M., Kleine-Weber, H., Krueger, N., Mueller, M. A., Drosten, C., Poehlmann, S.
10.1101/2020.01.31.929042 — Posted: 2020-01-31 Discussion: Onsite
The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes
Zhang, H., Kang, Z., Gong, H., Xu, D., Wang, J., Li, Z., Cui, X., Xiao, J., Meng, T., Zhou, W., Liu, J., Xu, H.
10.1101/2020.01.30.927806 — Posted: 2020-01-31 Discussion: Onsite
Engineered unnatural ubiquitin for optimal detection of deubiquitinating enzymes
Rut, W., Zmudzinski, M., Snipas, S. J., Bekes, M., Huang, T. T., Drag, M.
10.1101/2020.01.30.926881 — Posted: 2020-01-31
Estimated effectiveness of traveller screening to prevent international spread of 2019 novel coronavirus (2019-nCoV)
Gostic, K., Gomez, A. C. R., Mummah, R. O., Kucharski, A. J., Lloyd-Smith, J. O.
10.1101/2020.01.28.20019224 — Posted: 2020-01-30
Risk of 2019 novel coronavirus importations throughout China prior to the Wuhan quarantine
Du, Z., Wang, L., Cauchemez, S., Xu, X., Wang, X., Cowling, B. J., Meyers, L. A.
10.1101/2020.01.28.20019299 — Posted: 2020-01-30
Evolution and variation of 2019-novel coronavirus
Xiong, C., Jiang, L., Chen, Y., Jiang, Q.
10.1101/2020.01.30.926477 — Posted: 2020-01-30 Discussion: Onsite
Insights into Cross-species Evolution of Novel Human Coronavirus 2019-nCoV and Defining Immune Determinants for Vaccine Development
Ramaiah, A., Arumugaswami, V.
10.1101/2020.01.29.925867 — Posted: 2020-01-30 Discussion: Onsite
Estimating the effective reproduction number of the 2019-nCoV in China
Cao, Z., Zhang, Q., Lu, X., Pfeiffer, D., Jia, Z., Song, H., Zeng, D. D.
10.1101/2020.01.27.20018952 — Posted: 2020-01-29 Discussion: Onsite
Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines
Liu, X., Wang, X.-J.
10.1101/2020.01.29.924100 — Posted: 2020-01-29
Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening
Li, Y., Zhang, J., Wang, N., Li, H., Shi, Y., Guo, G., Liu, K., Zeng, H., Zou, Q.
10.1101/2020.01.28.922922 — Posted: 2020-01-29 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).